Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Advanced Cell Technology, Inc. announced today that it has completed key animal studies in connection with its Phase I multicenter study using embryonic stem cell derived Retinal Pigment Epithelium (RPE) cells to treat patients with Stargardt's Macular Dystrophy (SMD), for which it filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) in November. The studies demonstrated an excellent safety profile with no safety signals such as tumors or ectopic tissues.

24 Apr 2010

New gene therapy to restore retinal cone function and day vision

Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness.

22 Apr 2010

IP Advocate founder settles long-standing legal battle with UGARF

In a move that positions IP Advocate for its next chapter as a champion of research translation, founder Dr. Renee Kaswan today announced that she has settled her long-standing legal battle with the University of Georgia Research Foundation.

21 Apr 2010

Effects of UV radiation may increase chance of developing eye problems later in life

While 85 percent of Americans recognize that ultraviolet rays can damage their eyes, only 65 percent wear sunglasses as protection, and even fewer (39 percent) make sure their children wear sunglasses. By comparison, 78 percent make sure their children wear sunscreen when outdoors.

21 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Minnesota OMC's $20.9M series 2010 revenue bonds rated 'BBB-' by Fitch

Fitch Ratings assigns a 'BBB-' rating to the following City of Rochester, Minnesota health care facilities revenue bonds: --$20.9 million series 2010 revenue bonds (Olmsted Medical Center Project).

17 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Spring is busting out all over - and so are eye allergies

Ah, spring. The time of year when trees and flowers bloom sending pollen into the air and causing sneezing, runny noses and watery eyes. The Asthma & Allergy Foundation of America estimates that 1 in 5 individuals are affected by eye allergies.

15 Apr 2010

eRNA molecules are key players in brain development, says study

How does the brain work? This question is one of the greatest scientific mysteries, and neurobiologists have only recently begun to piece together the molecular building blocks that enable human beings to be "thinking" animals.

15 Apr 2010

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

An ophthalmologist at Washington University School of Medicine in St. Louis is implanting radioactive discs in the eyes of children with a rare cancer in an attempt to save their vision and their eyes.

15 Apr 2010

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Implanting blue light-filtering intraocular lenses during cataract surgery helps maintain visual function and may preserve the health of the retina, specifically in disease states such as age-related macular degeneration, according to a comprehensive review published in the May/June 2010 edition of Survey of Ophthalmology.

13 Apr 2010

Tufts Medical Center researchers discover new biological pathway for advanced AMD

Researchers at Tufts Medical Center and collaborators discovered a new biological pathway for advanced age-related macular degeneration that implicates a role of the hepatic lipase gene, LIPC. This discovery will improve understanding of the disease by providing researchers another developmental pathway to explore for prevention and treatment.

13 Apr 2010

Lockheed Martin pledges $4M to aid UCLA Health System's Operation Mend program

The Lockheed Martin Corp. announced today a pledge of $4 million to benefit the UCLA Health System's Operation Mend program, which provides reconstructive surgeries and other health care needs to U.S. military personnel wounded in Iraq and Afghanistan.

13 Apr 2010

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies, Inc. announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device.

12 Apr 2010

Team of neurologists from the U.S. face Canadian neurologists in annual "Neurobowl"

In a competition modeled after TV quiz shows, a team of neurologists from the United States will face Canadian neurologists in the annual "Neurobowl®" on April 11.

12 Apr 2010

People without migraines can filter out more visual noise: Study

When people feel the onset of a migraine headache, they may head to a dark, quiet room to rest. This instinct may be sound: A new study suggests that even without the headache, migraine sufferers may process visual cues better in an environment with few visual distractions.

12 Apr 2010

OptiMedica releases new details on femtosecond laser system for cataract surgery

OptiMedica Corp., a global ophthalmic device company, has released new details regarding the development of its proprietary femtosecond laser system for cataract surgery. The new system, which combines OptiMedica's breakthrough pattern scanning technology, an ultra-fast laser and integrated Optical Coherence Tomography imaging, is designed to dramatically improve the complex cataract procedure by replacing its most technically demanding and manual steps.

12 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

IRIDEX announces acquisition of certain assets from RetinaLabs

IRIDEX Corporation today announced that it has acquired certain assets from RetinaLabs, Inc., a privately held company based in Atlanta, Georgia. RetinaLabs develops and markets innovative retinal instrumentation used by ophthalmologists to perform vitreoretinal procedures in the operating room and the surgery center.

9 Apr 2010

Ophthalmology News and Research

Further Reading

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

New gene therapy to restore retinal cone function and day vision

IP Advocate founder settles long-standing legal battle with UGARF

Effects of UV radiation may increase chance of developing eye problems later in life

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Minnesota OMC's $20.9M series 2010 revenue bonds rated 'BBB-' by Fitch

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Spring is busting out all over - and so are eye allergies

eRNA molecules are key players in brain development, says study

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Tufts Medical Center researchers discover new biological pathway for advanced AMD

Lockheed Martin pledges $4M to aid UCLA Health System's Operation Mend program

Competitive Technologies to introduce Calmare pain therapy at medical conference

Team of neurologists from the U.S. face Canadian neurologists in annual "Neurobowl"

People without migraines can filter out more visual noise: Study

OptiMedica releases new details on femtosecond laser system for cataract surgery

Tβ4 therapy for ocular disorders closer to reality

IRIDEX announces acquisition of certain assets from RetinaLabs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News